MedTrace Logo

Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report

NCT02955862 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1177

Last updated 2018-03-29

No results posted yet for this study

Summary

CRICS financial report for the first budget year of the study

Conditions

  • Cryptococcal Meningitis

Interventions

OTHER

Vietnam Cryptococcal Retention in Care Study (CRICS)

Drug: Fluconazole HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole. Other Names: • Fluconazole

Sponsors & Collaborators

  • National Hospital for Tropical Diseases, Hanoi, Vietnam

    lead OTHER_GOV

Principal Investigators

  • Nguyen V Kinh, Dr · NHTD

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02955862 on ClinicalTrials.gov